Fimbrion Therapeutics Inc.
St. Louis, MO
- UEI
- N9RQX3G4EH54
- CAGE
- 5AAV6
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 20 S Sarah St, St. Louis, MO 63108, USA
- Website
- fimbrion.com
- Founded
- 2012
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
About Fimbrion Therapeutics Inc.
Fimbrion Therapeutics Inc. is a for-profit corporate entity based in St. Louis, Missouri, registered in the System for Award Management (SAM.gov) with a current registration valid through August 2026. The company specializes in pharmaceutical research and development, focusing on creating novel small molecule compounds to address challenging infectious disease treatments. Their core scientific expertise appears centered on developing innovative antimicrobial drug candidates targeting complex bacterial infections with significant unmet medical needs.
Fimbrion Therapeutics Inc. has received multiple project grants from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program, each valued around $300,000. Their research focuses on developing targeted therapeutic interventions for challenging bacterial infections, including tuberculosis, non-tuberculous mycobacteria, Pseudomonas aeruginosa, and urinary tract infections. Specific research projects include developing thiazolino-pyridone compounds as novel antimycobacterial drugs, creating small molecule glycoside inhibitors to disrupt bacterial biofilm formation, designing heterocyclic inhibitors targeting specific respiratory proteins in mycobacteria, and developing antibody-recruiting molecules to prevent complicated urinary tract infections. Each grant represents a two-year research effort aimed at advancing preclinical development of potential new drug candidates with novel mechanisms of action to combat antimicrobial resistance and improve treatment outcomes for difficult-to-treat bacterial infections.
Quick answers
What is Fimbrion Therapeutics Inc.'s UEI?
Fimbrion Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is N9RQX3G4EH54.
What is Fimbrion Therapeutics Inc.'s CAGE code?
Fimbrion Therapeutics Inc.'s CAGE code is 5AAV6.
What is Fimbrion Therapeutics Inc.'s primary NAICS code?
Fimbrion Therapeutics Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Fimbrion Therapeutics Inc. located?
Fimbrion Therapeutics Inc.'s physical address in SAM.gov is 20 S Sarah St, St. Louis, MO 63108, USA.
Is Fimbrion Therapeutics Inc. registered in SAM.gov?
Yes. Fimbrion Therapeutics Inc.'s SAM.gov registration is active through August 6, 2027.
What is Fimbrion Therapeutics Inc.'s most recent federal award?
Fimbrion Therapeutics Inc.'s most recent federal grant award is Thiazolino-pyridone compounds as novel antimycobacterial drugs for tuberculosis - project summary/abstract… (R43AI192175), from National Institute of Allergy and Infectious Diseases, on September 9, 2025.
On GovTribe
See Fimbrion Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors